Delving into the Latest Updates on 20-valent Pneumococcal Conjugate Vaccine(Pfizer) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

+ [1]

Synonyms

Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine

+ [13]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases

Active Indication

invasive Streptococcus pneumoniae infectionOtitis MediaPneumococcal Infections+ [5]

Inactive Indication

COVID-19Influenza, Human

Originator Organization

Wyeth Pharmaceuticals LLC

Active Organization

Pfizer Inc.Wyeth Pharmaceuticals LLC

Pfizer Japan, Inc.

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (08 Jun 2021),

Invasive streptococcal disease

RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US)

Login to view timeline

Structure/Sequence

Sequence Code 1148399

The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label
All participants in this study will receive Prevenar 20 vaccine.
1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.
We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.
Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

Start Date01 Sep 2025

Sponsor / Collaborator

Pfizer Inc.

CTRI/2024/12/077626

/ Not yet recruitingPhase 4IIT

A Phase IV, Open labelled, Randomized, Controlled Study to Assess the Immunogenicity and Effect on Pneumococcal Nasopharyngeal Carriage of reduced two dose schedule (1+1) of Pneumococcal Conjugate Vaccines 10-valent PNEUMOSIL and 14 valent PNEUBEVAX-14 as compared to their recommended three dose schedule (2+1) in Healthy Indian Infants. - NIL

Start Date01 Jan 2025

Sponsor / Collaborator-

NCT06622109

/ Active, not recruitingNot Applicable

PREVENAR 20 SUSPENSION LIQUID FOR INJECTION SPECIAL INVESTIGATION - Investigation in Infants Starting Vaccination at the Age of 2 Month, Inclusive, to 7 Months, Exclusive -

The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.
This study is seeking for infants aged between two months to six months who are vaccinated with PREVENAR 20 for the first time.
Infants aged between two months and six months are normally given four vaccinations. The first three vaccinations are called primary vaccinations and are given with an interval of one month between each vaccination. The fourth vaccination is called the booster and is given between 12 and 15 months of age.
Participants will take part in this study from the day of first vaccination to 28 days after fourth vaccination.
The side effects observed in the participants will be recorded and looked into.

Start Date25 Nov 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Translational Medicine associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Patents (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

3,187

Literatures (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

31 Dec 2025·Expert Review of Vaccines

Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China

Article

Author: Wang, Chaofan ; Zhang, Haijun ; Lai, Xiaozhen ; Deloria Knoll, Maria ; Wahl, Brian ; Fang, Hai ; Zhang, Haonan

BACKGROUND:

The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.

RESEARCH DESIGN AND METHODS:

A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.

RESULTS:

Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.

CONCLUSIONS:

Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach

Article

Author: Cassell, Kelsie ; Owusu-Edusei, Kwame ; Mueller, Peter P. ; Tajima, Atsushi ; Johnson, Kelly D. ; Yi, Zinan ; Cossrow, Nicole ; Matsuki, Taizo

INTRODUCTION:

This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.

METHODS:

A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level. Pneumococcal serotype distribution and vaccine effectiveness, as well as direct and indirect treatment costs and health-related utilities, were derived from published sources. The model used a lifetime horizon and 2% discounting of costs and life-years. Costs were adjusted to 2023 values in Japanese yen (¥). Outcomes were cases and deaths, life-years and quality-adjusted life-years (QALYs), vaccination and treatment costs, and incremental cost-effectiveness ratios. The range over which V116 was cost-saving and cost-effective was determined.

RESULTS:

Compared to PCV20, V116 averted an additional 28 cases of IPD, 918 cases of NBPP, 5 deaths from IPD, and 51 deaths from NBPP over the lifetime of a single age 65 cohort. Life-years and QALYs gained were 1,019 and 642, respectively, relative to PCV20; V116 saved ¥733 million in direct medical costs and ¥557 million in indirect costs, compared to PCV20. V116 was found to be cost-saving at price premiums up to ¥1,322 (payer perspective) or ¥2,327 (societal perspective) and remained below a willingness-to-pay threshold of ¥5 million/QALY for premiums up to ¥7,113 (payer perspective) or ¥8,117 (societal perspective).

CONCLUSIONS:

V116 is projected to provide more population health benefits in Japan than PCV20, and to be cost-effective at a variety of price premiums.

01 Feb 2025·VACCINE

Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines

Review

Author: Cho, Jeong-Yeon ; Chaiyakunapruk, Nathorn ; Vietri, Jeffrey ; Lee, Haeseon ; Wannaadisai, Warisa

BACKGROUND:

The economic and public health benefits of adult pneumococcal vaccines vary across countries due to different epidemiology and costs. We systematically reviewed and summarized findings and assumptions of cost-effectiveness analyses (CEA) of the recently introduced 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) in adults.

METHODS:

We performed a systematic search for CEA studies of PCV15 and/or PCV20 versus existing strategies via PubMed, EMBASE, CEA Registry, EconLit, HTA Database, and NITAG resource center through April 23, 2024. Study characteristics, methods, assumptions, and findings were extracted independently by two reviewers; quality was assessed using ECOBIAS. Results were synthesized qualitatively to summarize key attributes and conclusions.

RESULTS:

Of 137 identified records, 26 studies were included; the majority (24/26) concerned high-income countries. All employed static Markov-type models comparing higher-valent PCVs used alone or in combination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) to current recommendations (PPSV23 alone, PCV13 alone, PCV13 + PPSV23, no vaccination). Most studies (22/26) concluded PCV20 used alone was cost-saving (dominant) or cost-effective compared to other adult pneumococcal strategies (PPSV23 alone, PCV13 ± PPSV23, PCV15 ± PPSV23, or no vaccination). PCVs were generally assumed to have serotype-specific effectiveness equal to PCV13 efficacy in the pivotal trial, though four studies used estimates from a Delphi panel; protection was assumed to last between 10 and 20 years. PPSV23 was assumed to have lower effectiveness against non-bacteremic pneumonia and shorter duration of protection. Herd effects from higher-valent PCVs in childhood (12/26), serotype replacement (2/26), or both (1/26) were included in half (13/26) of studies, which attenuated adult vaccine impact. Most studies were assessed as low risk of bias; five abstracts did not provide sufficient information for assessment.

CONCLUSION:

Current evidence indicates that 20-valent PCV used alone is likely to be cost-effective or dominate other adult pneumococcal strategies. Future research is needed to address remaining uncertainties in assumptions and to support evidence-based policymaking.

114

News (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

02 Jan 2025

·www.biopharmadive.com

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

Happy New Year! We hope you had a restful holiday; If you took a break from keeping up with biotech news, weve got you covered with a brief rundown of the most important updates from the past week and a half.Pfizer wont move forward with asking regulators to approve a gene therapy for hemophilia A and instead will hand back rights to development partner Sangamo Therapeutics in a blow to the California-based biotechnology company. In a Dec. 30 statement, Sangamo CEO Sandy Macrae said his company was surprised and extremely disappointed by Pfizers decision, which comes some five months after the treatment met its goal in a Phase 3 study of people with the inherited bleeding disorder. Sangamo plans to search for an optimal path forward, which could include partnering with another company. Pfizer has steadily retreated from gene therapy, although it sells a hemophilia B gene therapy called Beqvez that it obtained from Spark Therapeutics. Ned PagliaruloRoche and Ideaya Biosciences acquired rights to similar, experimental lung cancer drugs in separate deals with China-based biotechnology companies. First, Ideaya on Monday paid Hengrui Pharma $75 million upfront for an antibody-drug conjugate that targets the protein delta-like ligand 3, or DLL3, and is currently in preclinical testing. Roche followed on Thursday by paying Innovent Biologics $80 million for a DLL3-targeting ADC that began a Phase 1 trial last month. Both drugs are being evaluated against small-cell lung cancer, a more aggressive and less common form of the disease. Ben FidlerAfter many years of effort, Novartis has obtained positive results from a Phase 3 study for a form of its spinal muscular atrophy gene therapy Zolgensma thats delivered via spinal injection rather than intravenous infusion. Data from the study, called Steer, showed treatment improved motor abilities in people with the neuromuscular disease who were two years of age or older and could still sit but had never walked independently. U.S. regulators suspended testing of the intrathecal formulation in late 2019 over safety concerns, but in August 2021 permitted Novartis to begin the Steer study. Novartis plans to share the new data with health authorities to support approval of the gene therapy in a broader range of people with spinal muscular atrophy. Ned PagliaruloBioNTech will pay the National Institutes of Health $792 million to settle disputes over use of patented technology to develop the mRNA COVID-19 vaccine Comirnaty, marketed by Pfizer, according to a securities filing.The payment will consist of $750 million worth of claimed royalties for the years 2020 through 2023 and $42 million for an amended license agreement that sets new royalty terms. Separately, BioNTech said it has settled with the University of Pennsylvania over patents related to technology used to develop Comirnaty, paying up to $467 million to Penn. Pfizer will reimburse BioNTech $365 million related to the NIH settlement and up to $170 million related to the Penn settlement. Jonathan GardnerAxsome Therapeutics intends to ask regulators for approval of a combination drug its developed to treat agitation caused by Alzheimers disease, despite mixed results from the companys latest late-stage trials. In one Phase 3 study, Axsomes drug, called AXS-05, lowered the risk of relapse in agitation versus placebo. However, AXS-05 missed its goal in another trial. Drawing on positive data from two prior studies, Axsome said it will submit a U.S. approval application in the second half of the year, which analysts expect may still be granted. Ned PagliaruloSanofi and partner SK Bioscience are expanding their partnership as they begin Phase 3 testing of a next-generation pneumococcal conjugate vaccine in children. The shot is designed to protect against 21 serotypes of Streptococcus pneumoniae and, according to Sanofi, is the first of its type targeting more than 20 to enter a Phase 3 trial in infants. The planned trial program will include over 7,700 infants, children and adolescents. If successful, the companies shot could eventually compete with Pfizers Prevnar 20, which in 2023 received a green light from the Food and Drug Administration for use in infants and children. Sanofi and SK Bioscience will co-fund research and development costs, while SK Bioscience will receive a 50 million euros upfront payment from Sanofi. Delilah AlvaradoThe Food and Drug Administration has approved Hikma Pharmaceuticals generic version of Novo Nordisks daily GLP-1 shot for diabetes, Victoza. First approved in 2010, Victoza once was the biggest selling drug in the class. But by 2023 its sales had declined to 8.7 billion kroner, or about $1.3 billion, while revenue from the more potent weekly GLP-1 shot Ozempic has grown since its 2017 launch. Teva Pharmaceutical launched an authorized generic of Victoza in June 2024. Jonathan Gardner '

Phase 3Drug ApprovalVaccineClinical ResultPhase 1

23 Dec 2024

·www.fiercebiotech.com

Sanofi pays SK bioscience €50M as children\'s pneumococcal vaccine enters phase 3

The partnership between Sanofi and SK bioscience dates back to 2014, when the French pharma paid $23 million upfront to get the ball rolling on vaccine development.\n Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3.The move follows a phase 2 win last year for the candidate, a 21-valent pneumococcal conjugate vaccine previously called GBP410 and now renamed PCV21, which demonstrated comparable immunogenicity to a control vaccine.By including 21 serotypes, the partners aim to offer broader coverage than the current approved pneumococcal conjugate vaccines for children. Sanofi announced Monday morning that it has now launched the shot into a phase 3 study, making it the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a late-stage study in infants and toddlers.Sanofi and SK will co-fund the research and development costs, with Sanofi also paying SK the 50 million euro upfront fee. An undisclosed amount of development and commercial milestone payments could follow. Should PCV21 make it to market, Sanofi will commercialize the vaccine worldwide, except for in SK’s home turf of South Korea.“Given the vast unmet public health needs in [invasive pneumococcal disease], we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV,” Thomas Triomphe, Sanofi\'s head of vaccines, said in the Dec. 23 release.“Our collaboration leverages SK bioscience’s capabilities and Sanofi’s expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease,” Triomphe added. The partnership between Sanofi and SK dates back to 2014, when the French pharma paid $23 million upfront to get the ball rolling on vaccine development.There are currently two FDA-approved pneumococcal vaccines for children—Merck & Co.’s 15-valent Vaxneuvance and Pfizer’s 20-valent Prevnar 20.Sanofi isn’t the only Big Pharma hoping to expand the range of serotypes available in pneumococcal vaccines. GSK had been working on a 24-valent candidate acquired via its $2.1 billion acquisition of Affinivax but revealed in October that it had axed the asset. In June, Merck’s 21-valent Capvaxive became the first pneumococcal vaccine specifically designed for adults to receive FDA approval.Then, in September, Vaxcyte unveiled what analysts called “stunning” phase 1/2 data in adults for its 31-valent candidate that, if replicated in a large pivotal study, could pose a serious threat to Prevnar 20. A separate phase 2 trial of Vaxcyte’s shot in infants has recently launched.

$Sanofi pays SK bioscience €50M as children\'s pneumococcal vaccine enters phase 3$

Phase 2Phase 3VaccineAcquisitionClinical Result

23 Dec 2024

·www.pharmaceutical-technology.com

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

SK bioscience retains exclusive rights in Korea, with Sanofi handling other markets and paying royalties on international sales. Credit: SK bioscience. SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension leverages their ongoing efforts with GBP410, a paediatric vaccine candidate entering Phase III trials. Under the new agreement, Sanofi will make an upfront payment of €50m ($52.1m) to SK bioscience, with additional potential milestones. Research and development expenses will be shared equally, whereas Sanofi will cover all commercialisation expenses. SK bioscience retains exclusive rights in Korea, with Sanofi handling other markets and paying royalties on international sales. Sanofi Vaccines executive vice-president Thomas Triomphe said: “Given the vast unmet public health needs in IPD, we’re delighted to extend this collaboration and continue our pursuit of innovative work in PCV. Our collaboration leverages SK bioscience’s capabilities and Sanofi’s expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease.” The extended partnership includes the development of PCVs for adult use, aiming to provide comprehensive protection against pneumococcal infections. The initiation of the Phase III clinical programme for GBP410 marks it as the first candidate with over 20 serotypes in this trial phase for infants and toddlers. Phase III studies globally will assess the therapy’s safety and immunogenicity in more than 7,700 subjects who are aged six weeks to 17 years. The trials will involve up to four doses, based on the enrolment age. SK bioscience CEO Jaeyong Ahn said: “Our decision to develop next-generation PCVs and simultaneously initiate phase III clinical programme for GBP410 reflects the GBP410’s high potential for success, a promising market outlook, and our strong mutual trust. “As Korea’s leading company in the vaccine and bio-industry, we are committed to successfully bringing vaccines with blockbuster potential to market that will secure vaccine sovereignty, contribute to global health, and lead the global market.” In preparation for GBP410’s commercialisation, SK bioscience began expanding its ‘L House’ manufacturing facility at Andong, Gyeongsangbuk-do, South Korea in March, with Sanofi’s joint investment. The ground-breaking ceremony for L House took place in March 2024.

VaccinePhase 3License out/in

100 Deals associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
invasive Streptococcus pneumoniae infection	KR	Pfizer Pharmaceuticals Korea Ltd.	31 Oct 2024
Otitis Media	US	Wyeth Pharmaceuticals LLC	27 Apr 2023
Pneumococcal Infections	CA	Pfizer Canada ULC	09 May 2022
Pneumonia, Pneumococcal	EU	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	IS	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	LI	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	NO	Pfizer Europe MA EEIG	14 Feb 2022
Invasive streptococcal disease	US	Wyeth Pharmaceuticals LLC	08 Jun 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	NDA/BLA	EU	Pfizer Europe MA EEIG	26 Jan 2024
Respiratory Syncytial Virus Infections	NDA/BLA	US	Pfizer Inc.	17 May 2023
COVID-19	Phase 3	US	Pfizer Inc.	20 May 2021
Influenza, Human	Phase 3	US	Pfizer Inc.	01 Sep 2020
Infectious Lung Disorder	Phase 2	US	Pfizer Inc.	05 Jun 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05886777 (CTgov)	Phase 2	COVID-19 \| Infectious Lung Disorder	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	eeewvrlbga(joduhowtzo) = huicmzdrif tnqthcggxg (rdclqgphte, tuvfduuyll - nhahltufad) View more	-	18 Dec 2024
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	eeewvrlbga(joduhowtzo) = shibsthqxs tnqthcggxg (rdclqgphte, fmnnufvzyx - bwfeobompo) View more
NCT05875727 (CTgov)	Phase 3	Pneumococcal Infections	405	Pneumococcal vaccine (Cohort 1: 18 to 49 Years)	xytqxdwvzs(yptjrabsyg) = winybixquv xavchvmfws (qpfjbucdat, hbrgmljbjo - wyzwfqjarv) View more	-	24 Oct 2024
				Pneumococcal vaccine (Cohort 2: >= 50 Years)	xytqxdwvzs(yptjrabsyg) = yjxycjiwlp xavchvmfws (qpfjbucdat, atvzlgdftj - ttgkurofhm) View more
NCT05408429 (CTgov)	Phase 3	Pneumococcal Infections	356	20vPnC (2-Dose 20vPnC)	bjrrogyknm(cemixkkchd) = kxxqtuowyy pkfxrykgmb (alljjgkigf, agecrpixfx - ztwfmypqso) View more	-	19 Sep 2024
				20vPnC (1-Dose 20vPnC)	bjrrogyknm(cemixkkchd) = ojpsjupmww pkfxrykgmb (alljjgkigf, rcgxdpbjzz - yiofqrpgko) View more
NCT04382326 (CTgov)	Phase 3	Pneumococcal Infections	1,997	20-valent Pneumococcal Conjugate Vaccine (20vPnC) (20vPnC)	dvgcidkmik(mttlrxcucr) = mcucdgbzav wfjfgcolhs (zahxuruzof, lxmulcbgnx - efkghemukd) View more	-	06 Dec 2023
				13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC)	dvgcidkmik(mttlrxcucr) = xgspcqvgyv wfjfgcolhs (zahxuruzof, qciqdabeve - dpjvlpvcoz) View more
NCT04379713 (CTgov)	Phase 3	Pneumococcal Infections	1,511	20vPnC (20vPnC)	ejjrdpxfsp(fxkklmctas) = athimczmef juzauceutj (wvzsirvaqs, aqtpfykzks - kbqqbmwtzh) View more	-	13 Jun 2023
				13vPnC (13vPnC)	ejjrdpxfsp(fxkklmctas) = ebrauxxepj juzauceutj (wvzsirvaqs, jellvovjfu - xhuisevhcw) View more
NCT04642079 (CTgov)	Phase 3	Pneumococcal Infections	839	20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months)	aglnqfgcly(gmchkydxsx) = lwgycksdky xablnyffit (xagdgcyvtj, zgmbalkvli - ejcckpyumh) View more	-	26 Apr 2023
				20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years)	aglnqfgcly(gmchkydxsx) = nuuqzcyvxi xablnyffit (xagdgcyvtj, rwqvemrfed - gpiskxrfdb) View more
NCT04530838 (CTgov)	Phase 3	Pneumococcal Infections	668	20vPnC (20vPnC (SC))	ghzqddgusn(zpfcobapkg) = uqifnnpbut kjpjmwdhxx (ltramynnos, ddovrgsycc - gwvjsrgukj) View more	-	21 Apr 2023
				13vPnC (13vPnC (SC))	ghzqddgusn(zpfcobapkg) = omxnnknzfw kjpjmwdhxx (ltramynnos, zsabtbwuwm - rhgbnekspq) View more
NCT04887948 (CTgov)	Phase 3	COVID-19 \| Pneumococcal Infections	570	BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)	dhqezmylkz(tgczgexfbp) = zbmsmdlzgq tkrdrsalud (ficqbpkdxw, jqotqycfkt - eckcwnlvru) View more	-	14 Dec 2022
				BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)	dhqezmylkz(tgczgexfbp) = dnhihqxeyj tkrdrsalud (ficqbpkdxw, rjzebmgyns - ebcmpcobax) View more
NCT04546425 (Corporate Publications) Manual	Phase 3	Pneumococcal Infections	-	20-Valent Pneumococcal Conjugate Vaccine	krsbeeiwfr(qlhpmifkxj) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated rzjjddwucs (pukaoyhaxl )	Non-inferior	19 Sep 2022
				Prevenar 13
NCT04382326 (Corporate Publications) Manual	Phase 3	IRAK4 Deficiency	-	20-Valent Pneumococcal Conjugate Vaccine	dyqnhfixqc(kxfhrdewub) = A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events (decreased appetite, drowsiness, and irritability) rpynuavlhz (snpgdibxpq )	Non-inferior	12 Aug 2022
				Pneumococcal polysaccharide conjugate vaccine